<?xml version="1.0" encoding="UTF-8"?>
<p>A randomized, phase 3 clinical trial of 5 versus 10 days of remdesivir, sponsored by Gilead Sciences, is enrolling patients with severe COVID-19 (ClinicalTrials.gov identifier: NCT04292899). Primary outcomes are the odds of ratio for improvement on a seven-point ordinal scale on day 14.
 <xref rid="cit0037" ref-type="bibr">37</xref> Another phase 3, randomized trial of remdesivir (ClinicalTrials.gov identifier: NCT04292730) is the same as NCT04292899 except patients enrolling in that study undergo moderate COVID-19. The primary outcome is the proportion of subjects discharged by day 11.
 <xref rid="cit0038" ref-type="bibr">38</xref>
</p>
